Inflammatory mediator production (None)

*Inflammatory mediator production* is **not a single molecular target**, but rather describes the **biological process by which cells synthesize and release substances—such as cytokines, chemokines, eicosanoids like prostaglandins and leukotrienes, histamine, serotonin—responsible for initiating and regulating inflammation in response to injury or infection.[1][2][3]**\n\nKey cell types involved include macrophages, mast cells, neutrophils—and endothelial cells—which produce these mediators upon activation by pathogens or tissue damage.[1][4] The released molecules act locally and systemically to increase vascular permeability; recruit immune cells; induce pain sensation; promote fever; and orchestrate both acute defense mechanisms against pathogens/injury as well as chronic pathological processes if dysregulated.[4]\n\nThe term "inflammatory mediator production" is therefore **too broad/vague for use as a canonical drug target name**, since it encompasses multiple distinct molecular targets—including enzymes like cyclooxygenases/lipoxygenases,[2] receptors such as interleukin receptors,[3] transcription factors like NF-kappaB,[3] among others—that can each be specifically targeted by different classes of therapeutics.\n\n> “Inflammatory mediators are substances released by cells in the immune system that help modulate inflammation…such as cytokines [IL‑1β], prostaglandins [PGE₂], histamine.”[1]\n\n> “Primary inflammatory stimuli…activate intracellular signaling pathways that then activate production of inflammatory mediators.”[3]\n\nIn summary: *Inflammatory mediator production* refers to an essential physiological process—not an individual molecule/receptor/therapeutic target—and should not be listed alongside canonical drug targets without further specification.

Other names

Production of inflammatory mediatorsSynthesis of inflammatory mediatorsInflammatory mediator biosynthesis

Not applicable directly. For drugs acting on this process: Enzyme inhibition (e.g., COX inhibitors block prostaglandin synthesis); Cytokine blockade with monoclonal antibodies or receptor antagonists